FDA Clearance Tracker · K182988
Afinion HbA1c Dx on Afinion 2
Last checked: Nov 20, 2026Latest source record: Nov 29, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Nov 29, 2018
Substantially Equivalent
Time to decision
31 days
Received Oct 29, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K182988
- Device name
- Afinion HbA1c Dx on Afinion 2
- Applicant
- Alere Technologies AS
- Applicant location
- Oslo, NO
- Received
- Oct 29, 2018
- Decided
- Nov 29, 2018
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device type
- Hemoglobin A1c Test System (PDJ)
- Device class
- Class II
- Regulation
- 21 CFR 862.1373
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PDJ. The earliest in FDA's data is DEN130002, decided May 23, 2013.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K182988
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Alere Technologies AS
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Afinion HbA1c Dx510(k)
K180296 · Decided May 7, 2018 · 94 days after receipt
Device type: Hemoglobin A1c Test System (PDJ) · Laboratory Medicine & Pathology
K151809 · Decided Sep 25, 2015 · 85 days after receipt
Device type: Assay, Glycosylated Hemoglobin (LCP) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.